Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Stem cell disease model reveals how tumor suppressor may drive bone cancer

Stem cell disease model reveals how tumor suppressor may drive bone cancer

Pharmacyclics announces positive results from IMBRUVICA Phase II study in WM patients

Pharmacyclics announces positive results from IMBRUVICA Phase II study in WM patients

Astellas Pharma, MD Anderson sign option agreement to research and develop new treatment for AML

Astellas Pharma, MD Anderson sign option agreement to research and develop new treatment for AML

Clinical trial uses personalized cellular therapy to treat GVHD complication of bone marrow transplant

Clinical trial uses personalized cellular therapy to treat GVHD complication of bone marrow transplant

Leukemia drug could prevent and control growth of colorectal tumours

Leukemia drug could prevent and control growth of colorectal tumours

Research may point to new paradigms in diagnosis, treatment of aggressive cancers

Research may point to new paradigms in diagnosis, treatment of aggressive cancers

Novel molecule inhibits cancer-causing transcription factors

Novel molecule inhibits cancer-causing transcription factors

Old leukemia drug may help in fight against cancer

Old leukemia drug may help in fight against cancer

Low doses of imatinib drug can push immune system to combat bacterial infections

Low doses of imatinib drug can push immune system to combat bacterial infections

TSRI scientists uncover unique mechanism of natural product with antimicrobial, anti-cancer effects

TSRI scientists uncover unique mechanism of natural product with antimicrobial, anti-cancer effects

Selvita commences IND-enabling studies for its first oncology drug candidate

Selvita commences IND-enabling studies for its first oncology drug candidate

New study sheds light on natural small molecule with antimicrobial effects

New study sheds light on natural small molecule with antimicrobial effects

Genetic markers may predict tumor samples that respond to treatment

Genetic markers may predict tumor samples that respond to treatment

New drug shows potential against rare type of acute leukemia

New drug shows potential against rare type of acute leukemia

Amgen receives FDA priority review designation for Kyprolis to treat relapsed multiple myeloma

Amgen receives FDA priority review designation for Kyprolis to treat relapsed multiple myeloma

New faculty members join UNC Lineberger to help launch immunotherapy clinical trials

New faculty members join UNC Lineberger to help launch immunotherapy clinical trials

CASI receives CFDA approval for ENMD-2076 Phase 2 clinical trial in ovarian clear cell carcinoma

CASI receives CFDA approval for ENMD-2076 Phase 2 clinical trial in ovarian clear cell carcinoma

Stopping cellular quality-control mechanism can make chemotherapy more effective

Stopping cellular quality-control mechanism can make chemotherapy more effective

Radiation resistance in leukemia can be overcome by using new precision medicine, say researchers

Radiation resistance in leukemia can be overcome by using new precision medicine, say researchers

UVA researchers develop compound that could lead to improved leukemia treatments

UVA researchers develop compound that could lead to improved leukemia treatments

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.